{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:54:13Z","timestamp":1790952853120,"version":"4.1.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The no-reflow phenomenon is defined as inadequate microvascular reperfusion despite successful epicardial coronary recanalization, associated with multiple adverse outcomes, occurring in up to 7% of primary PCI. Its multifactorial pathophysiology includes endothelial injury, distal embolization, and vasospasm. Thus, intracoronary epinephrine has shown promising results due to its vascular regulation. Then, this meta-analysis evaluates the role of epinephrine to treat and prevent the no-reflow phenomenon.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following Preferred reporting Items for Systematic Reviews and Meta-Analysis standards, we systematically searched MEDLINE, Scopus, Embase, Cochrane, and Web of Science for studies comparing epinephrine with conventional therapy or other drugs. The primary outcome was thrombolysis in myocardial infarction (TIMI) flow. Secondary outcomes included major adverse cardiovascular events (MACE), heart failure, mortality, left ventricular ejection fraction, and myocardial blush grade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eleven studies (700 epinephrine, 298 control) were included. TIMI flow was assessed using single-arm meta-analyses, stratified into refractory and primary no-reflow. TIMI 3 flow was achieved in 63% of refractory and 86% of primary. Myocardial blush grade 3 was achieved in 47.4% of cases. MACE incidence was 14% in refractory and 18% in primary no-reflow. Compared with conventional treatment, epinephrine reduced MACE risk (risk ratio 0.45; 95% confidence interval: 0.23\u20130.87;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.01;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u20050%) but showed no difference versus adenosine. Heart failure incidence was 11% in controls and 5% in adenosine, without significant comparative differences.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Therefore, intracoronary epinephrine was associated with encouraging but exploratory findings, and the higher success rate in primary no-reflow may reflect earlier intervention and less severe microvascular damage. Its modest advantage over adenosine suggests potential therapeutic value, though evidence remains limited and heterogeneous.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mca.0000000000001632","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T11:01:14Z","timestamp":1774263674000},"page":"491-502","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Back to the flow: a comprehensive systematic review and meta-analysis of epinephrine in the treatment of no-reflow"],"prefix":"10.1097","volume":"37","author":[{"given":"Leonardo","family":"Dexheimer da Silva","sequence":"first","affiliation":[{"name":"Department of Medicine, University of S\u00e3o Paulo, S\u00e3o Paulo\/SP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Cadorin","family":"de Ara\u00fajo","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of S\u00e3o Paulo, S\u00e3o Paulo\/SP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduarda","family":"Dexheimer da Silva","sequence":"additional","affiliation":[{"name":"Department of Medicine, Federal University of Santa Maria, Santa Maria\/RS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kau\u00e3 Gabriel","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of S\u00e3o Paulo, S\u00e3o Paulo\/SP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Fonseca Oliveira","family":"Suruagy-Motta","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cesmac University Center, Macei\u00f3\/AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Rodrigues","family":"Moreira","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of S\u00e3o Paulo, S\u00e3o Paulo\/SP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Rezende","family":"Neves","sequence":"additional","affiliation":[{"name":"Department of Medicine, State University of Par\u00e1, Bel\u00e9m\/PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Alexandre","family":"Farias","sequence":"additional","affiliation":[{"name":"Department of Medicine, University Ninth of July UNINOVE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Galv\u00e3o","family":"de Oliveira Oldra","sequence":"additional","affiliation":[{"name":"Department of Medicine, Anhembi Morumbi University, S\u00e3o Paulo\/SP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Antonio Machado Gomes","family":"de Sousa","sequence":"additional","affiliation":[{"name":"Department of Medicine, Federal University of Uberl\u00e2ndia, Uberl\u00e2ndia\/MG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Augusto Bento","family":"de Sousa","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of S\u00e3o Paulo, S\u00e3o Paulo\/SP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"da Silva Ribeiro","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of S\u00e3o Paulo, S\u00e3o Paulo\/SP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Sobreira","family":"Spina","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Heart Institute of University of S\u00e3o Paulo Medical School, S\u00e3o Paulo\/SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalgi","family":"Modi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Louisiana State University, Shreveport, Louisiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"R1-20261002","doi-asserted-by":"crossref","first-page":"e013738","DOI":"10.1161\/CIRCINTERVENTIONS.123.013738","article-title":"No-reflow prediction in acute coronary syndrome during percutaneous coronary intervention: the NORPACS risk score.","volume":"17","author":"Dawson","year":"2024","journal-title":"Circ Cardiovasc Interv"},{"key":"R2-20261002","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.3390\/jcm11082233","article-title":"\"No-Reflow\" phenomenon: a contemporary review.","volume":"11","author":"Annibali","year":"2022","journal-title":"J Clin Med"},{"key":"R3-20261002","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1161\/CIRCULATIONAHA.107.742312","article-title":"Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention.","volume":"117","author":"Jaffe","year":"2008","journal-title":"Circulation"},{"key":"R4-20261002","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0735-1097(01)01405-X","article-title":"Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction.","volume":"38","author":"Iwakura","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"R5-20261002","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jcin.2016.11.059","article-title":"Management of no-reflow phenomenon in the catheterization laboratory.","volume":"10","author":"Rezkalla","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"R6-20261002","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/heart.87.2.162","article-title":"The \"no-reflow\" phenomenon: basic science and clinical correlates.","volume":"87","author":"Reffelmann","year":"2002","journal-title":"Heart"},{"key":"R7-20261002","doi-asserted-by":"crossref","first-page":"e1003583","DOI":"10.1371\/journal.pmed.1003583","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"18","author":"Page","year":"2021","journal-title":"PLoS Med"},{"key":"R8-20261002","doi-asserted-by":"crossref","first-page":"5","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package.","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"R9-20261002","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"R10-20261002","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool.","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"key":"R11-20261002","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R12-20261002","first-page":"829","article-title":"Assessment of the strength of recommendation and quality of evidence: GRADE checklist. A descriptive study.","volume":"140","author":"Bezerra","year":"2022","journal-title":"Sao Paulo Med J"},{"key":"R13-20261002","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12872-015-0004-6","article-title":"Intracoronary epinephrine in the treatment of refractory no-reflow after primary percutaneous coronary intervention: a retrospective study.","volume":"15","author":"Aksu","year":"2015","journal-title":"BMC Cardiovasc Disord"},{"key":"R14-20261002","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5144\/0256-4947.2022.75","article-title":"Intracoronary epinephrine versus adenosine in the management of refractory no-reflow phenomenon: a single-center retrospective cohort study.","volume":"42","author":"Darwish","year":"2022","journal-title":"Ann Saudi Med"},{"key":"R15-20261002","doi-asserted-by":"crossref","first-page":"512","DOI":"10.5603\/cj.102975","article-title":"Intracoronary adrenaline for the treatment of refractory no-reflow phenomenon: a single-centre experience.","volume":"32","author":"Desperak","year":"2025","journal-title":"Cardiol J"},{"key":"R16-20261002","first-page":"436","article-title":"Intracoronary verapamil vs. intracoronary epinephrine in the management of coronary no reflow during primary percutaneous coronary intervention.","volume":"14","author":"Hafez","year":"2021","journal-title":"Interv Cardiol"},{"key":"R17-20261002","doi-asserted-by":"crossref","first-page":"510","DOI":"10.55519\/JAMC-03-13041","article-title":"Frequency Of no-reflow in patients undergoing primary percutaneous coronary intervention and the impact of intracoronary adrenaline and tirofiban on timi flow.","volume":"36","author":"Hamidullah","year":"2024","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"R18-20261002","doi-asserted-by":"crossref","first-page":"e011408","DOI":"10.1161\/CIRCINTERVENTIONS.121.011408","article-title":"Comparison of intracoronary epinephrine and adenosine for no-reflow in normotensive patients with acute coronary syndrome (COAR Trial).","volume":"15","author":"Khan","year":"2022","journal-title":"Circ Cardiovasc Interv"},{"key":"R19-20261002","first-page":"305","article-title":"Resolution of refractory no-reflow with intracoronary epinephrine.","volume":"57","author":"Skelding","year":"2002","journal-title":"Catheter Cardiovasc Interv"},{"key":"R20-20261002","first-page":"602","article-title":"Efficacy and safety of intracoronary epinephrine versus conventional treatments alone in STEMI patients with refractory coronary no-reflow during primary PCI: The RESTORE observational study.","volume":"97","author":"Navarese","year":"2021","journal-title":"Catheter Cardiovasc Interv"},{"key":"R21-20261002","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.amjcard.2024.07.011","article-title":"Efficiency and safety of intracoronary epinephrine administration in patients with ST-elevation myocardial infarction with refractory coronary no-reflow.","volume":"226","author":"Ryabov","year":"2024","journal-title":"Am J Cardiol"},{"key":"R22-20261002","doi-asserted-by":"crossref","first-page":"34","DOI":"10.18087\/cardio.2024.6.n2493","article-title":"Intracoronary administration of epinephrine in the refractory no-reflow phenomenon in patients with acute myocardial infarction.","volume":"64","author":"Vyshlov","year":"2024","journal-title":"Kardiologiia"},{"key":"R23-20261002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.33425\/2639-8486.1120","article-title":"Distal intracoronary delivery of epinephrine versus verapamil to prevent no-reflow during primary percutaneous coronary intervention: a randomized, open-label, trial.","volume":"5","author":"Yassin","year":"2021","journal-title":"Cardiol Vasc Res"},{"key":"R24-20261002","doi-asserted-by":"crossref","first-page":"H1515","DOI":"10.1152\/ajpheart.00955.2004","article-title":"Microvascular oxygen delivery and consumption following treatment with verapamil.","volume":"288","author":"Hangai-Hoger","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"5 Pt 2","key":"R25-20261002","first-page":"II47","article-title":"Effects of epinephrine on coronary microvascular diameters.","volume":"61","author":"Chilian","year":"1987","journal-title":"Circ Res"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MCA.0000000000001632","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:00:38Z","timestamp":1790949638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MCA.0000000000001632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001632","relation":{},"ISSN":["0954-6928","1473-5830"],"issn-type":[{"value":"0954-6928","type":"print"},{"value":"1473-5830","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]}}}